280x280_PEZALLA_Ed_headshot_Feb 2017
Former President
Aetna International

Edmund J. Pezalla, MD, MPH, is a leading innovator in payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways.


Ed is the former vice president for pharmaceutical policy and strategy in the office of the chief medical officer at Aetna. In this position he developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage.


Ed is active as a payer expert on a number of policy working groups including the New Drug Development Paradigm Project at MIT. He has recently been named a Scholar-in-Residence at the Duke-Margolis Health Policy Center in Washington, DC where he is working on policy approaches to stimulating the development of new antimicrobials, evaluation of value frameworks, and other policy projects. Ed is a member of the Board of Directors of the Pharmacy Quality Alliance and the Connecticut Biosciences Innovation Fund. He is also a member of the Business Advisory Board of Naia Pharmaceuticals and the Scientific Advisory Board of Temple Therapeutics.


Ed received his BS in Biophysics from Georgetown University College of Arts and Sciences, and his MD Cum Laude from Georgetown University School of Medicine. He holds a Master’s in Public Health from the University of California at Berkeley and was a health services research fellow and doctoral student in health policy at the University of Michigan.


Ed has co-authored a number of papers on adaptive licensing and other drug development issues and was an invited expert contributing to the report on Accelerating Innovation in Drug Development from the President’s Council of Advisors on Science and Technology.

None yet.